Understanding the role of Early Value Assessment for technology adoption in the NHS.
Health Technology Assessment is becoming increasingly used by health authorities globally to assess the clinical and economic effectiveness of Heath Technologies. Early value assessment (EVA) is a tool used by the National Institute for Health and Care Excellence (NICE) to assess those technologies that address unmet need and align with the NHS Long-Term Plan.
This approach allows rapid assessment of digital products, devices and diagnostics for clinical effectiveness and value for money, so, the NHS and patients can benefit from these promising technologies sooner. Reports on products assessed using the EVA approach are published in reports addressing unmet need, existing evidence and identing key gaps in evidence.
Costs: SEHTA Members – £80+VATpp / Non-Members – £120+VATpp
Not a member of SEHTA – register for basic FREE membership here
To find out more information, view the schedule, and register your place, please click here.